HIV Rapid Testing Market - Forecast(2024 - 2030)

Report Code: HCR 1574 Report Format: PDF + Excel

HIV Rapid Testing Market Overview:

HIV Rapid Testing Market size is estimated to reach $15.07 billion by 2030, growing at a CAGR of 7.22% during the forecast period 2024-2030. HIV rapid testing has emerged as a crucial diagnostic tool for Human Immunodeficiency Virus (HIV), offering swift results typically within minutes. Utilizing a small sample of blood or oral fluid, these tests identify the presence of HIV antibodies or antigens in the body. The market for HIV Rapid Testing is witnessing substantial growth, propelled by the escalating incidence of HIV infections on a global scale. This diagnostic method plays a pivotal role in early detection and timely intervention, contributing to effective disease management and public health strategies.
The HIV Rapid Testing market is experiencing substantial growth, primarily propelled by the escalating incidence of HIV infections on a global scale. This concerning rise in HIV cases has become a pivotal factor driving the demand for rapid testing solutions. Governments worldwide are responding to this public health challenge by increasing investments in comprehensive HIV prevention, testing, and treatment programs. The concerted efforts of governments to curb the spread of HIV involve substantial financial allocations to testing initiatives. This heightened focus on prevention and early detection is significantly fueling the demand for HIV rapid testing technologies. As a result, the market for these testing solutions is witnessing a robust upswing, driven by the imperative need for efficient and quick diagnostics in the ongoing efforts to combat the spread of HIV and improve patient outcomes.
Additionally, the convergence of technological advancements in rapid testing methods and concerted efforts in public health infrastructure has positioned HIV rapid testing as a cornerstone in the global fight against HIV/AIDS. The intersection of increasing infection rates and proactive governmental measures underscores the critical role played by HIV rapid testing in identifying cases promptly, facilitating timely treatment, and contributing to broader public health objectives.

Market Snapshot: 

HIV Rapid Testing Market - Report Coverage:
The “HIV Rapid Testing Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the HIV Rapid Testing Market.



By HIV Type

  • HIV 1

  • HIV 2

By Sample Type

  • Blood

  • Fingerstick

  • Venous Blood Draw

  • Oral Fluid

  • Serum

  • Plasma

  • Urine

By Test Type

  • Antibody Rapid Test

  • Antigen Rapid Test

  • Antigen/Antibody Combination Test

By Technology

  • Immunofiltration

  • Lateral flow Immunoassay

  • Enzyme-Linked immunosorbent assay (ELISA)

  • Chemiluminescent Immunoassay (CLIA)

  • Fluorescence Immunoassay (FIA)

By Demographics

  • Gender

  • Male

  • Female

  • Age

  • 13-25

  • 26-50

  • Above 50

By Test Generation

  • 2nd

  • 3rd

  • 4th

By Application

  • Facility Administered Kit

  • Self-Test Kit 

By End User

  • Diagnostic Laboratories

  • Hospitals

  • Blood Bank

  • Home Care Settings

  • Specialty clinics

  • Others

By Distribution Channel

  • Pharmacy/Drugs Store

  • Retail Shops

  • Others

By Geography

  • North America (U.S., Canada and Mexico)

  • Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe),

  • Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific),

  • South America (Brazil, Argentina, Chile, Colombia and Rest of South America)

  • Rest of the World (Middle East and Africa).

COVID-19 / Ukraine Crisis - Impact Analysis:  

● The COVID-19 pandemic has left an indelible mark on global healthcare, impacting various facets of diagnostic testing, including the HIV rapid testing market. The disruptions caused by lockdowns and social distancing measures have led to a reduction in routine healthcare services, affecting the accessibility of HIV testing. Individuals' hesitancy or inability to seek in-person healthcare services has contributed to a decline in testing rates, potentially resulting in delayed or missed HIV diagnoses. The reprioritization of healthcare resources and funding towards managing the immediate challenges posed by COVID-19 has led to a shift in priorities, affecting the implementation of HIV testing programs. Despite these challenges, the pandemic has spurred innovations, with an increased emphasis on telehealth services and self-testing options. 

● The ongoing crisis in Ukraine has the potential to impact various sectors, including healthcare, and may influence the landscape of the HIV rapid testing market in several ways. Disruptions in healthcare infrastructure due to conflict-related damage, shortages of medical supplies, and the displacement of healthcare professionals can hinder the availability and accessibility of healthcare services, including HIV testing. The crisis-induced population displacement and vulnerability may make at-risk populations more susceptible to health challenges, limiting their access to testing facilities and healthcare resources. Resource diversion towards addressing immediate humanitarian needs and emergency healthcare may result in a redirection of funds and attention away from routine healthcare programs, impacting HIV testing initiatives. 

Key Takeaways:

● Fastest Growth of Asia-Pacific Region
Geographically, in the global HIV Rapid Testing Market share, Asia-Pacific is analyzed to grow with the highest CAGR of 8.91% during the forecast period 2024-2030. The Asia-Pacific (APAC) region has emerged as the epicenter of substantial growth in the HIV Rapid Testing Market, largely attributed to proactive measures taken by governments such as Vietnam. The Vietnamese government's concerted efforts to expand access to HIV testing and treatment have significantly contributed to this positive trajectory. In recent years, a targeted approach has been adopted, focusing on key populations at higher risk of HIV transmission, including individuals who inject drugs, men who have sex with men, and sex workers. By prioritizing these populations, the government aims to enhance early detection and treatment outcomes. Notably, the provision of free HIV testing and antiretroviral therapy (ART) to those in need has played a pivotal role in fostering a comprehensive and accessible healthcare infrastructure. As a result, these initiatives have become instrumental in fueling the growth of the HIV Rapid Testing Market across the Asia-Pacific region, underscoring the significance of tailored public health interventions in shaping the market landscape.

● Facility Administered Kit segment to Register the Fastest Growth
HIV testing services are vital in preventing the spread of the virus, and they can be categorized as either conventional facility-based or community-based. Facility-based testing, as outlined in a WHO facts sheet from July 2022, encompasses tests conducted at health facilities either upon client request or through healthcare provider-initiated testing and counseling. The global HIV landscape reflects the significance of testing, with 38.4 million people living with HIV at the end of 2021 and 1.5 million new infections. These kits contribute to early detection, preventing further transmission and facilitating prompt medical intervention. Consequently, the HIV rapid testing market, particularly the Facility Administered Kit segment, witnessed significant growth, generating $644.77 million in revenue in 2022. Projections indicate further expansion, with an expected revenue of $1081.40 million by 2030, showcasing a notable compound annual growth rate (CAGR) of 6.64% during the period from 2024 to 2030.

● The Lateral Flow Immunoassay is the Fastest Growing Segment in the Market
Lateral Flow Immunoassay plays a pivotal role in the realm of rapid HIV testing, employing HIV 1 subtype B antigens to capture HIV-specific antibodies, primarily from the immunodominant transmembrane region., The Lateral Flow Immunoassay segment is poised for expansion, driven by the increasing demand for point-of-care testing. Notably, the rapidity of results and cost-effectiveness compared to alternative technologies contribute to the growth of the HIV rapid testing market. In 2022, the Lateral Flow Immunoassay segment generated a substantial revenue of $634.2 million, with projections indicating further growth to reach $1128.31 million by 2030, exhibiting a noteworthy compound annual growth rate (CAGR) of 7.43%. 

● Increasing prevalence of HIV is projected to fuel market growth
The escalating prevalence of HIV/AIDS is a driving force behind the robust growth of the HIV Rapid Testing market. Several factors contribute to the increasing cases of HIV, including a lack of awareness and education, pervasive stigma and discrimination, poverty, and limited access to healthcare services. According to the World Health Organization, HIV/AIDS remains a significant global public health challenge, with an estimated 38 million people living with the virus globally in 2021. Of this population, 36.7 million were adults, and 1.7 million were children under the age of 15. In 2021 alone, approximately 650,000 people died from HIV-related causes, while 1.5 million acquired the virus.
 Further insights from the Kaiser Family Foundation reveal that the global prevalence of HIV among adults has remained steady since 2001, with a rate of 0.7% in 2021. Sub-Saharan Africa bears the highest burden, housing two-thirds of all people living with HIV globally, followed by the regions of Asia and the Pacific. Latin America, Eastern Europe, and Central Asia are also significantly affected by the virus. In India, the Northeastern states exhibit the highest adult HIV prevalence, with Mizoram, Nagaland, and Manipur reporting rates of 2.70%, 1.36%, and 1.05%, respectively.

● High Cost of HIV Rapid Test
The high cost of HIV rapid tests presents a significant challenge that could potentially impede market growth. Various factors contribute to the cost of these tests, encompassing manufacturing expenses, quality assurance measures, research and development investments, distribution costs, regulatory compliance, and overall demand. When compared to traditional laboratory-based tests, HIV rapid tests tend to be more expensive, posing limitations on their accessibility and availability, particularly in low-resource settings. The pricing of an HIV rapid test can vary based on factors such as location, test type, and whether it is conducted at a public or private facility. On average, these tests range from $10 to $50 USD
Additionally, the implementation of rapid testing requires appropriate infrastructure and trained personnel for test administration and interpretation. In some settings, the lack of such infrastructure can constrain the availability of testing services. Despite their higher cost, HIV rapid tests offer the advantage of early diagnosis, contributing to their continued relevance and adoption over traditional laboratory-based tests. The challenge lies in finding ways to address cost barriers and enhance the accessibility of these critical testing services, particularly in resource-constrained environments. 
                                                                         HIV Rapid Testing Market Share (%) By Region, 2023
                                                                         For More Details on This Report - Request for Sample

Key Market Players: 

Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the HIV Rapid Testing Market. The top 10 companies in this industry are listed below:
1. Abbat
2. F.Hoffmann-La Roche AG
3. Bio-Rad Laboratories, Inc
4. Siemens Healthineers
5. Hologic Inc
6. Orasure Technologies, Inc
7. Danaher (Including Cephied)
8. BioMerieux Clinical Diagnostics
9. Quidel Corporation
10. Chembio Diagnostic Systems

Scope of Report: 

Report Metric


Base Year Considered


Forecast Period




Market Size in 2030

$15.07 billion

Segments Covered

HIV Type, Sample Type, Test Type, Technology, Demographics, Test Generation, Application, End User, Distribution Channel

Geographies Covered

North America (U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia, New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa).

Key Market Players

  • Abbat

  • F.Hoffmann-La Roche AG

  • Bio-Rad Laboratories, Inc

  • Siemens Healthineers

  • Hologic Inc

  • Orasure Technologies, Inc

  • Danaher (Including Cephied)

  • BioMerieux Clinical Diagnostics

  • Quidel Corporation

  • Chembio Diagnostic Systems

For more Lifesciences and Healthcare reports, please click here
1. HIV Rapid Testing Market - Overview
    1.1. Definitions and Scope
2. HIV Rapid Testing Market - Executive Summary
3. HIV Rapid Testing Market - Comparative Analysis
    3.1. Company Benchmarking - Key Companies
    3.2. Global Financial Analysis - Key Companies
    3.3. Market Share Analysis - Key Companies
    3.4. Patent Analysis
    3.5. Pricing Analysis
4. HIV Rapid Testing Market - Start-up Companies Scenario (Premium)
    4.1. Key Start-up Company Analysis by
        4.1.1. Investment
        4.1.2. Revenue
        4.1.3. Venture Capital and Funding Scenario
5. HIV Rapid Testing Market – Market Entry Scenario Premium (Premium)
    5.1. Regulatory Framework Overview
    5.2. New Business and Ease of Doing Business Index
    5.3. Case Studies of Successful Ventures
6. HIV Rapid Testing Market - Forces
    6.1. Market Drivers
    6.2. Market Constraints
    6.3. Market Challenges
    6.4. Porter's Five Force Model
        6.4.1. Bargaining Power of Suppliers
        6.4.2. Bargaining Powers of Customers
        6.4.3. Threat of New Entrants
        6.4.4. Rivalry Among Existing Players
        6.4.5. Threat of Substitutes
7. HIV Rapid Testing Market – Strategic Analysis
    7.1. Value Chain Analysis
    7.2. Opportunities Analysis
    7.3. Market Life Cycle
    7.4. Suppliers and distributors Analysis
8. HIV Rapid Testing Market – by HIV Type (Market Size – $Million/$Billion) 
    8.1. HIV 1
    8.2. HIV 2
9. HIV Rapid Testing Market – by Sample Type (Market Size – $Million/$Billion) 
    9.1. Blood
        9.1.1 Fingerstick
        9.1.2 Venous Blood Draw
9.2. Oral Fluid
    9.3 Serum
    9.4 Plasma
    9.5 Urine
10. HIV Rapid Testing Market – by Test Type (Market Size – $Million/$Billion)
    10.1. Antibody Rapid Test
    10.2. Antigen/Rapid Test
    10.3. Antigen /Antibody Combination Test
11. HIV Rapid Testing Market – by Technology (Market Size – $Million/$Billion) 
    11.1. Immunofilitration
    11.2. Lateral flow Immunoassy
    11.3. Enzyme-Linked immunosorbent (ELISA)
    11.4. Chemiluminescent Immunoassay (CLIA)
    11.5. Fluorescence Immunoassay (FIA)
12. HIV Rapid Testing Market – by Demographics (Market Size – $Million/$Billion) 
    12.1. Gender                   
    12.2. Male
    12.3. Female
    12.4. 26-50
    12.5. 13-25
    12.6. Above 50
13. HIV Rapid Testing Market – by Test Generation (Market Size – $Million/$Billion) 
    13.1. 2nd
    13.2. 3rd
    13.3. 4th
14. HIV Rapid Testing Market – by Application (Market Size – $Million/$Billion) 
    14.1. Facility Administered Kit
    14.2. Self-Test Kit
15. HIV Rapid Testing Market – by End User (Market Size – $Million/$Billion) 
    15.1. Diagnostic Laboratories
    15.2. Hospitals
    15.3. Blood Bank
    15.4. Home Care Settings
    15.5. Specialty Clinics
16. HIV Rapid Testing Market – by Distribution Channel (Market Size – $Million/$Billion) 
    16.1. Pharmacy/ Drugs Store
    16.2. Retail Shops
    16.3. Others
17. HIV Rapid Testing Market – by Geography (Market Size – $Million/$Billion) 
    17.1. North America
        17.1.1. U.S.
        17.1.2. Canada
        17.1.3. Mexico
    17.2. Europe
        17.2.1. France
        17.2.2. Germany
        17.2.3. Italy
        17.2.4. Netherlands
        17.2.5. Spain
        17.2.6. U.K
        17.2.7. Rest of Europe
    17.3. Asia-Pacific
        17.3.1. China
        17.3.2. Japan
        17.3.3. South Korea
        17.3.4. India
        17.3.5. Austrialia
        17.3.6. Indonesia
        17.3.7. Malaysia
        17.3.8. Rest of Asia- Pacific 
    17.4. South America
        17.4.1. Argentina
        17.4.2. Brazil
        17.4.3. Chile
        17.4.4. Rest of South America
    17.5. Rest of the World
        17.5.1. Middle East
        17.5.2. Africa
18. HIV Rapid Testing Market – Entropy
19. HIV Rapid Testing Market – Industry/Segment Competition Landscape Premium 
    19.1. Market Share Analysis
        19.1.1. Market Share by Product Type – Key Companies
        19.1.2. Market Share by Region – Key Companies
        19.1.3. Market Share by Country – Key Companies
    19.2. Competition Matrix
    19.3. Best Practices for Companies
20. HIV Rapid Testing Market – Key Company List by Country Premium Premium 
21. HIV Rapid Testing Market - Company Analysis
    21.1. Abbat
    21.2. F.Hoffmann-La Roche AG
    21.3. Bio-Rad Laboratories, Inc
    21.4. Siemens Healthineers
    21.5. Hologic Inc
    21.6. Orasure Technologies, Inc
    21.7. Danaher (Including Cephied)
    21.8. BioMerieux Clinical Diagnostics
    21.9. Quidel Corporation
    21.10. Chembio Diagnostic Systems

"Financials to the Private Companies would be provided on best-effort basis."

Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.

The HIV Rapid Testing Market is projected to grow at 7.22% CAGR during the forecast period 2023-2030.

Global HIV Rapid Testing Market size is estimated to be $924.94 million in 2023 and is projected to reach $15.07 billion by 2030.

The leading players in the HIV Rapid Testing Market are BioMerieux Clinical Diagnostics,\\\\r\\\\nF.Hoffmann-La Roche AG, Orasure Technologies, Inc and Others.

The demand for HIV testing kits, including the antigen/antibody combination test, has increased as a result and Increased HIV are some of the major HIV Rapid Testing Market trends in the industry which will create growth opportunities for the market during the forecast period.

Increasing prevalence of HIV, Government initiatives and Development of innovative HIV\\\\r\\\\nare the driving factors of the market.